ChromaDex: Difference between revisions
Content deleted Content added
m ty |
SVG logo |
||
| (41 intermediate revisions by 21 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Food ingredient company in California}} |
|||
{{Infobox company |
{{Infobox company |
||
| name = ChromaDex, Inc |
| name = ChromaDex, Inc |
||
| logo = |
| logo = ChromaDex_logo.svg |
||
| type = [[Public company|Public]] |
| type = [[Public company|Public]] |
||
| traded_as = NASDAQ |
| traded_as = {{NASDAQ|CDXC}}<br />[[Russell 2000 Index]] component |
||
| industry = [[Dietary supplements]], food ingredients |
| industry = [[Dietary supplements]], food ingredients, chemical sample analysis |
||
| foundation = 1999 |
| foundation = 1999 |
||
| location = [[ |
| location = [[Los Angeles, California]], United States |
||
| key_people = [[ |
| key_people = [[Rob Fried]]<br /><small>(CEO)</small><br />Frank Jaksch<br /><small>(Cofounder, Executive Chairman)</small> |
||
| products = |
| products = Tru Niagen |
||
| website = {{URL|https://www.chromadex.com/}} |
|||
| homepage = ChromaDex.com |
|||
}} |
}} |
||
| ⚫ | |||
| ⚫ | |||
ChromaDex has licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound trademarked as pTeroPure via the company's BluScience product line.<ref name="DM">{{cite web |url= http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title= Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb|first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= }}</ref> In 2011, [[Cornell University]] announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for [[nicotinamide riboside]] which it markets and sells as an ingredient under the brand name Niagen.<ref name="LEF">{{cite web |url= http://www.lef.org/newsletter/2007/2007_05_04.htm |title= Got nicotinamide riboside? |accessdate=2012-05-29 |date=2007-05-04 |work= |publisher=Life Extension |pages= |quote= }}</ref> |
|||
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref> |
|||
The firm also offers [[contract research organization|contract research]] services for sourcing [[raw materials]], identifingy new compounds, and developing processes for large scale manufacturing.<ref name="PPT">{{cite web|url=http://www.otcmarkets.com/stock/CDXC/profile|title=OTC Markets Stock Profile CDXC|date=|publisher=|pages=|quote=|accessdate=2016-03-21|work=OTC Markets}}</ref> |
|||
== History == |
|||
American billionaire and pharmaceutical [[entrepreneur]] [[Phillip Frost]] owns approximately 19% of the firm.<ref name="TREFIS1">{{cite web |url= http://www.trefis.com/stock/pfe/articles/123353/billionaire-phillip-frost-a-case-study-in-synergy/2012-05-28?from=filmstrip%3Atop |title= Billionaire Phillip Frost: A Case Study In Synergy |accessdate=2012-05-29 |last=Gould|first=David |date=5-3-2011 |work= |publisher=TREFIS |pages= |quote= }}</ref><ref name="CHROMADEX2">{{cite web |url= http://www.prnewswire.com/news-releases/chromadex-corp-names-consumer-products-veteran-jeffrey-himmel-ceo-137876133.html |title= ChromaDex Corp. Names Consumer Products Veteran Jeffrey Himmel CEO |accessdate=2012-05-29 |date=2012-01-23 |work= |publisher= |pages= |quote= }}</ref> |
|||
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013. |
|||
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018. |
|||
ChromaDex sells ingredients to third parties that market them under their own labels. [[Elysium Health]] bought the ingredients in its "Basis" product from ChromaDex.<ref name=Wired>{{cite news|last1=Zhang|first1=Sarah|title=The Weird Business Behind a Trendy "Anti-Aging" Pill|url=https://www.wired.com/2016/07/confused-elysiums-anti-aging-drug-yeah-fda/|work=Wired|date=July 6, 2016}}</ref> The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the head of manufacturing from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.<ref name=TC>{{cite news|last1=Buhr|first1=Sarah|title=A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier|url=https://techcrunch.com/2017/01/16/a-new-lawsuit-alleges-anti-aging-startup-elysium-health-hasnt-paid-its-supplier-and-is-in-breach-of-agreement/|work=TechCrunch|date=January 16, 2017}}</ref> |
|||
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development. |
|||
==See also== |
|||
* [[Resveratrol]] |
|||
==References== |
==References== |
||
{{Reflist |
{{Reflist}} |
||
==External links== |
==External links== |
||
* {{Official website|http://www.chromaDex.com}} |
* {{Official website|http://www.chromaDex.com}} |
||
{{Authority control}} |
|||
[[Category:Biotechnology companies of the United States]] |
[[Category:Biotechnology companies of the United States]] |
||
Latest revision as of 08:17, 19 October 2024
 | |
| Company type | Public |
|---|---|
| Nasdaq: CDXC Russell 2000 Index component | |
| Industry | Dietary supplements, food ingredients, chemical sample analysis |
| Founded | 1999 |
| Headquarters | Los Angeles, California, United States |
Key people | Rob Fried (CEO) Frank Jaksch (Cofounder, Executive Chairman) |
| Products | Tru Niagen |
| Website | www |
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[1] ChromaDex no longer sells pTeroPure.[2]
History
[edit]Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.
References
[edit]- ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
- ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.
